Adaptation of the GABAA‐receptor complex in rat brain during chronic elevation of GABA by ethanolamine O‐sulphate
Open Access
- 19 July 1987
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 91 (3) , 617-625
- https://doi.org/10.1111/j.1476-5381.1987.tb11255.x
Abstract
1 Slice preparations of rat cuneate nucleus were used for studies on the γ-aminobutyric acid GABAA-receptor complex following chronic and acute pretreatment with GABA-α-ketoglutarate aminotransferase (GABA-T) inhibitors. 2 The whole brain GABA concentration was significantly increased 2.9 fold and 2.6 fold following treatment with ethanolamine O-sulphate (EOS, orally) for 15–30 days and 56–64 days, respectively. One hour after a single injection of γ-acetylenic GABA (GAG) i.p., there was a significant 2.1 fold increase in whole brain GABA. 3 Superfusion of a slice with muscimol or the GABA uptake inhibitor nipecotic acid depolarized the afferent nerve fibres. These effects were potentiated by flurazepam (1 μm) and pentobarbitone (10 μm) and antagonized by picrotoxin (3 μm, 30 μm). 4 Following 15–30 days of EOS-treatment, the depolarization response to muscimol was decreased and that to nipecotic acid increased. These changes were no longer significant by 56–64 days of pretreatment. The acute dose of GAG did not affect the depolarization response to muscimol but increased that to nipecotic acid. 5 The potentiations of muscimol by flurazepam (1 μm) and pentobarbitone (10 μm) were enhanced following chronic EOS treatment (15–64 days). The enhancement of flurazepam was less after 56–64 days than after 15–30 days pretreatment whereas the enhancement of pentobarbitone was similar at both times. Acute GAG treatment had no effect. 6 The potency of picrotoxin as an antagonist of muscimol was reduced following chronic EOS treatment; the enhancement was less after 56–64 days than after 15–30 days pretreatment. Acute GAG treatment caused only a very small reduction in picrotoxin potency. 7 Possible adaptations in the GABAA-receptor complex and its modulation during chronic elevation of brain GABA are discussed.This publication has 24 references indexed in Scilit:
- Steroid Hormone Metabolites Are Barbiturate-Like Modulators of the GABA ReceptorScience, 1986
- On the Use of Enzyme Inhibitors to Study the Synthesis and Utilization of Brain GABAActa Pharmacologica et Toxicologica, 1984
- The perspective of GABA replenishment therapy in the epilepsies: A critical evaluation of hopes and concernsLife Sciences, 1983
- Effects of the glutamic acid decarboxylase inhibitor 3-mercaptopropionic acid on the synthesis of brain GABAin vivo and postmortallyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1983
- Evidence that bicuculline and picrotoxin act at separate sites to antagonize γ-aminobutyric acid in rat cuneate nucleusNeuropharmacology, 1980
- Dopamine Receptor Supersensitivity in the Corpus Striatum Following Chronic Elevation of Brain γ‐Aminobutyric AcidJournal of Neurochemistry, 1980
- γ‐VINYL GABA: EFFECTS OF CHRONIC ADMINISTRATION ON THE METABOLISM OF GABA AND OTHER AMINO COMPOUNDS IN RAT BRAINJournal of Neurochemistry, 1979
- REGIONAL LEVELS OF GABA IN THE BRAIN: RAPID SEMIAUTOMATED ASSAY AND PREVENTION OF POSTMORTEM INCREASE BY 3‐MERCAPTO‐PROPIONIC ACIDJournal of Neurochemistry, 1978
- L-Glutamic Acid Decarboxylase in Parkinson's Disease: Effect of L-Dopa TherapyNature, 1973
- SOME EFFECTS OF DIETARY VITAMIN B6 DEFICIENCY AND 4‐DEOXYPYRIDOXINE ON γ‐AMINOBUTYRIC ACID METABOLISM IN RAT BRAINJournal of Neurochemistry, 1972